Alumis Inc.(ALMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALMS Alumis Inc.

Pre-Mkt 08-25 09:23:59 EDT

23.03

-1.14

-4.72%

盘前23.23

+0.20+0.87%

08:44 EDT

High23.74	Low22.43	Vol850.80K
Open23.69	D1 Closing24.17	Amplitude5.42%
Mkt Cap2.97B	Tradable Cap2.53B	Total Shares129.00M
T/O19.50M	T/O Rate0.78%	Tradable Shares109.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":23.03,"timestamp":1787601600000,"preClose":24.17,"halted":0,"volume":850804,"hourTrading":{"tag":"盘前","latestPrice":23.23,"preClose":23.03,"latestTime":"08:44 EDT","volume":506,"amount":11769.260954000001,"timestamp":1787661879928,"change":0.2,"changeRate":0.008684,"amplitude":0.003799},"delay":0,"changeRate":-0.047165908150599935,"floatShares":109674768,"shares":129000000,"eps":-3.800544,"marketStatus":"Pre-Mkt","change":-1.14,"latestTime":"08-25 09:23:59 EDT","open":23.69,"high":23.74,"low":22.43,"amount":19496799.000940003,"amplitude":0.054199,"askPrice":23.23,"askSize":100,"bidPrice":23.1,"bidSize":80,"shortable":3,"etf":0,"ttmEps":-3.800544,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787664600000},"marketStatusCode":1,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":23.03,"preHourTrading":{"tag":"盘前","latestPrice":23.23,"preClose":23.03,"latestTime":"08:44 EDT","volume":506,"amount":11769.260954000001,"timestamp":1787661879928,"change":0.2,"changeRate":0.008684,"amplitude":0.003799},"postHourTrading":{"tag":"盘后","latestPrice":22.5325,"preClose":23.03,"latestTime":"19:50 EDT","volume":39032,"amount":898812.2235,"timestamp":1787615431851,"change":-0.4975,"changeRate":-0.021602,"amplitude":0.026131},"volumeRatio":0.9829552569843815,"optionData":{"bulkOrders":[{"symbol":"ALMS","call":true,"expireDate":1789704000000,"strike":"45.0","timestamp":1787587803017,"price":1.05,"volume":2500,"amount":262500,"type":"-"},{"symbol":"ALMS","call":true,"expireDate":1789704000000,"strike":"25.0","timestamp":1787587803017,"price":4.95,"volume":2500,"amount":1237500,"type":"+"}]},"impliedVol":2.0962,"impliedVolPercentile":0.944},"requestUrl":"/m/hq/s/ALMS/tweets","defaultTab":"tweets","newsList":[{"id":"2660041619","title":"What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2660041619","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660041619?lang=en_us&edition=fundamental","pubTime":"2026-08-19 09:22","pubTimestamp":1787102572,"startTime":"0","endTime":"0","summary":"Earlier in August 2026, Alumis Inc. reported second-quarter results showing revenue of US$1.66 million and a net loss of US$142.22 million, reversing a net profit a year earlier as loss per share widened sharply.\nA few days before that earnings release, Alumis reported positive topline Phase 3 ONWARD3 extension data for its oral TYK2 inhibitor envudeucitinib in plaque psoriasis and outlined plans to file a U.S. FDA New Drug Application this year, highlighting a potential first-in-class,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/what-alumis-almss-envudeucitinib-phase-3-data-and-deepening","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/what-alumis-almss-envudeucitinib-phase-3-data-and-deepening","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126741","title":"Alumis Publishes Corporate Deck on Next-Generation TYK2 Inhibitors for Immune-Mediated Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126741","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126741?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:07","pubTimestamp":1786738077,"startTime":"0","endTime":"0","summary":"Alumis publishes corporate deck on next-generation TYK2 inhibitors for immune-mediated diseasesAlumis highlighted Phase 3 psoriasis efficacy for envudeucitinib, citing Week 24 PASI 100 of 41% in ONWAR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL2KXKqr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659112583","title":"Alumis Price Target Maintained with a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2659112583","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659112583?lang=en_us&edition=fundamental","pubTime":"2026-08-15 01:36","pubTimestamp":1786728960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659992141","title":"Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Cabaletta Bio (CABA) and Capricor Therapeutics (CAPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659992141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659992141?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:40","pubTimestamp":1786711234,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alumis Inc. (ALMS), Cabaletta Bio (CABA) and Capricor Therapeutic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alumis-inc-alms-cabaletta-bio-caba-and-capricor-therapeutics-capr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alumis-inc-alms-cabaletta-bio-caba-and-capricor-therapeutics-capr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","XLV","ALMS","CAPR","BK4139","CABA","BK4581","XBI","HCSG","BK4585","BK4007","LU0128526141.USD","LU0029874061.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659149406","title":"Guggenheim Keeps Their Buy Rating on Alumis Inc. (ALMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659149406","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659149406?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:17","pubTimestamp":1786709870,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Yatin Suneja from Guggenheim reiterated a Buy rating on Alumis Inc., with a price target of $34.00. The company’s s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-alumis-inc-alms-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-alumis-inc-alms-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659816019","title":"Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659816019","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659816019?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:59","pubTimestamp":1786654767,"startTime":"0","endTime":"0","summary":"Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.71) by 56.34 percent. This is a 12.6 percent increase over losses of $(1.27) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61196225/alumis-q2-eps-1-11-misses-0-71-estimate-sales-1-662m-miss-3-468m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659975160","title":"Alumis Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659975160","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659975160?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:57","pubTimestamp":1786654665,"startTime":"0","endTime":"0","summary":"Alumis Inc. reports results for the quarter ended June 30 - Earnings SummaryAlumis Inc.ALMS.OQreported a quarterly adjusted loss of 79 cents per share for the quarter ended June 30, higher than the sa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A27H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659164039","title":"Alumis Q2 FY26 Net Loss Widens to $142.22 Million; Revenue Falls 37.65% to $1.66 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659164039","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659164039?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651290,"startTime":"0","endTime":"0","summary":"Alumis Q2 FY26 net loss widens to $142.22 million; revenue falls 37.65% to $1.66 millionAlumis posted a net loss of $142.2 million for Q2 2026, swinging from net income of $59.3 million a year earlier","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL8CQkwM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014039.USD","BK4112","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014005.SGD","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","ALMS","BCDF","LU2210149790.SGD","BK4007","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167954","title":"Alumis - to Initiate Phase 2 Trial for A-005 in Parkinson's Disease in 1H 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167954?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651261,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA697Z2D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167672","title":"Alumis - on Track to Submit Nda for Envudeucitinib in Pso to FDA in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167672","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167672?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651261,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA697Z2D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659640971","title":"Press Release: Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2659640971","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659640971?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651260,"startTime":"0","endTime":"0","summary":"that 75% and 54% of patients achieved PASI 90 and PASI 100, respectively,after up to 48 weeks of continuous envudeucitinib treatment , with. envudeucitinib well tolerated and a safety profile consistent with. -- Alumis remains on track to submit its New Drug Application to FDA for. envudeucitinib in PsO in the fourth quarter of 2026.-- Alumis plans to present additional long-term envudeucitinib data at","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4077","ALMS","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659652481","title":"Alumis Inc. (ALMS) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2659652481","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659652481?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:35","pubTimestamp":1786635345,"startTime":"0","endTime":"0","summary":"In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Alumis Inc., with a price target of $44.00. According...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alumis-inc-alms-receives-a-rating-update-from-a-top-analyst-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alumis-inc-alms-receives-a-rating-update-from-a-top-analyst-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658957988","title":"Alumis reports strong Phase 3 data for envudeucitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2658957988","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658957988?lang=en_us&edition=fundamental","pubTime":"2026-08-11 06:15","pubTimestamp":1786400134,"startTime":"0","endTime":"0","summary":"Alumis Inc. ( ($ALMS) ) has issued an announcement. On August 10, 2026, Alumis reported topline long-term extension data from its Phase 3 ONWARD3 s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alumis-reports-strong-phase-3-data-for-envudeucitinib?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alumis-reports-strong-phase-3-data-for-envudeucitinib?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959748","title":"Alumis - Envudeucitinib Shows Consistent Safety Profile with no New Safety Signals in Onward3","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959748","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959748?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393214,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471PP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959712","title":"Alumis - Topline Data from Lumus Phase 2B Trial in Lupus Expected in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959712?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393214,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471PP:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658790959","title":"Alumis - to Submit Nda to FDA for Envudeucitinib in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2658790959","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658790959?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393214,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471PP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658597679","title":"Alumis - 75% of Patients Achieve Pasi 90, 54% Achieve Pasi 100 After 48 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2658597679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658597679?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393214,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471PP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658594439","title":"Alumis Says Envudeucitinib Hits 54% PASI 100 at 48 Weeks in Onward3 Plaque Psoriasis Extension Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2658594439","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658594439?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:16","pubTimestamp":1786393015,"startTime":"0","endTime":"0","summary":"Alumis says envudeucitinib hits 54% PASI 100 at 48 weeks in ONWARD3 plaque psoriasis extension studyAlumis reported topline long-term extension results for envudeucitinib in moderate-to-severe plaque ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDLbXgvJt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952654","title":"Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952654","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658952654?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:05","pubTimestamp":1786392300,"startTime":"0","endTime":"0","summary":"– ONWARD3 data show 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of continuous envudeucitinib treatment –  – Favorable long-term safety and tolerability profile remained c","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3342219/0/en/envudeucitinib-long-term-data-positioned-to-set-a-new-standard-for-plaque-psoriasis-treatment-delivering-highest-reported-pasi-100-skin-clearance-among-oral-therapies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4124","ALMS","SMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656320725","title":"Alumis: Competitive Pressures and Dosing Drawbacks Support Hold Rating and Unchanged $25 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2656320725","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656320725?lang=en_us&edition=fundamental","pubTime":"2026-08-03 18:15","pubTimestamp":1785752131,"startTime":"0","endTime":"0","summary":"Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Hold rating on Alumis Inc., retaining the price target of $25.00. Mitchell Kapoor has given...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alumis-competitive-pressures-and-dosing-drawbacks-support-hold-rating-and-unchanged-25-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alumis-competitive-pressures-and-dosing-drawbacks-support-hold-rating-and-unchanged-25-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alumis.com","stockEarnings":[{"period":"1week","weight":-0.0969},{"period":"1month","weight":-0.1775},{"period":"3month","weight":0.0313},{"period":"6month","weight":-0.2164},{"period":"1year","weight":3.7583},{"period":"ytd","weight":1.3596}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1014},{"period":"1year","weight":0.1831},{"period":"ytd","weight":0.1196}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alumis Inc. was incorporated on January 29, 2021, as a Delaware corporation. It is a clinical-stage biopharmaceutical company initially focused on developing two tyrosine kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor designed to achieve maximal target inhibition, and A-005, a CNS-penetrant molecule. The company's mission is to significantly improve patients' lives by replacing broad immunosuppression with targeted therapies.","exchange":"NASDAQ","name":"Alumis Inc.","nameEN":"Alumis Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alumis Inc.(ALMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alumis Inc.(ALMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alumis Inc.,ALMS,Alumis Inc.股票,Alumis Inc.股票老虎,Alumis Inc.股票老虎国际,Alumis Inc.行情,Alumis Inc.股票行情,Alumis Inc.股价,Alumis Inc.股市,Alumis Inc.股票价格,Alumis Inc.股票交易,Alumis Inc.股票购买,Alumis Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alumis Inc.(ALMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alumis Inc.(ALMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}